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ABSTRACT

Gernant, Stephanie A, PharmD, MS. Purdue University, May 2015. The Impact of Care
Coordination in Community-Pharmacist Delivered Medication Therapy Management.
Major Professor: Margie E Snyder, PharmD, MPH

Background: Care coordination is imperative to successful patient outcomes. However,
community pharmacists are commonly excluded from health information exchange
during care coordination. One of the ways pharmacists deliver care, through medication
therapy management (MTM), could be optimized if pharmacists engaged in care
coordination through review of unedited patient medical records in preparation for a
section of the MTM, the comprehensive medication review (CMR).

Methods: This was a non-blinded randomized controlled trial undertaken within the
Medication Safety Research network of Indiana, also known as RxSafeNet. RxSafeNet is a
community pharmacy practice based research network. Pharmacists were randomized
to deliver CMR’s to adult patients under usual care, or with a care coordination
intervention. The intervention consisted of soliciting the patient-identified primary care
provider-held medical records of the last six months. Medication related problems
(MRPs) identified and omissions in preventative care identified were recorded for each
CMR delivered. Additionally, pharmacists were surveyed over their thoughts and
opinions regarding utilizing medical records.

ix
Results: Thirty seven patients were seen for CMR appointments. Intervention
pharmacists identified more MRP’s than usual care pharmacists. The intervention,
while controlling for predictor variables included in a multiple linear regression model,
had an adjusted R2= 0.511; p=0.05. Intervention pharmacists identified more omissions
in preventative care (adjusted R2= 0.136; p=0.027).
Intervention pharmacists were more likely to agree they were confident they identified
all of the patient’s MRPs (47.1% vs. 15.8%), but neither group was more likely than the
other to believe they had resolved all MRPs (41.2% vs. 42.1%). Lastly, intervention
pharmacists agreed 100% of the time that the patient’s health history helped them
complete a better CMR as compared with only 69% of usual care pharmacists.

Conclusion: Community pharmacists identify more MRPs and omissions in preventative
care when they engage in care coordination by reviewing the patient’s PCP’s unedited
medical record in preparation for a CMR.

1

INTRODUCTION

One of the many ways community pharmacists deliver patient care is through
Medication Therapy Management, otherwise known as “MTM.” MTM can be thought of
as an umbrella term referring to a group of services pharmacists offer, such as
medication therapy reviews and pharmacotherapy consults, which are utilized to
identify, prevent, and resolve medication-related problems (MRPs)(American
Pharmacist Association 2013). Effective MTM is imperative, as an estimated 1.5 million
preventable medication-related adverse effects at an expense of $177 billion occur each
year in the United states(Ernst and Grizzle 2001). However, evidence of MTM’s
effectiveness has varied extensively (Fox, Ried et al. 2009, Pindolia, Stebelsky et al.
2009, Welch, Delate et al. 2009, Winston and Lin 2009, Moczygemba, Barner et al. 2011,
Ward and Xu 2011) and this variation can be attributed to a lack of service
standardization and optimization. One of the Core Elements of MTM, the
Comprehensive Medication Review (CMR), is a process that could be targeted for such
optimization. CMRs consist of pharmacists’ review and reconciliation of a patient’s
prescription and non-prescription medications to promote overall health and identify
MRPs. Unfortunately the effectiveness of CMRs may be limited due to the lack of care
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coordination (i.e. sharing of available patient health information) among health
professionals (Hume, Kirwin et al. 2012). Thus the ability of community pharmacists to
detect and resolve health-related problems, either medication related or preventivecare related, may be diminished.
Evidence from numerous studies show that when pharmacists engage in care
coordination, positive impacts such as enhanced medication-related problem detection
and resolution are realized. This has resulted in many hospitals including pharmacists in
admission, discharge and follow-up programs (Bolas, Brookes et al. 2004, Schnipper,
Kirwin et al. 2006, Kramer, Hopkins et al. 2007, Kwan, Fernandes et al. 2007, Varkey,
Cunningham et al. 2007, Gorgas Torner, Gamundi Planas et al. 2008, Midlov, Holmdahl
et al. 2008, Bergkvist, Midlov et al. 2009, Walker, Bernstein et al. 2009, Eggink,
Lenderink et al. 2010, Hellstrom, Bondesson et al. 2011, Midlov, Bahrani et al. 2012).
However, similar care coordination efforts in the community setting are limited. It is
unknown how out-patient pharmacists in the community utilize medication records in
preparation for a CMR.

Needs Assessment
The United States Agency for Healthcare Research and Quality (AHRQ), as a part of the
Department of Health and Human Services, defines care coordination as “the deliberate
organization of patient care activities between two or more participants (including the
patient)…,” and “the exchange of information among participants responsible for
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different aspects of care”(McDonald, Sundaram et al. 2007). The Centers for Medicare
and Medicaid Services (CMS) and the Institute of Medicine (IOM) have identified poor
care coordination as a major health problem within the United States, due to its
staggering risk to patient safety: sixty-six percent of all medication-related errors are
attributed to poor care coordination(Santell 2009). Consequently, standardized and
effective mechanisms are needed to facilitate effective health information exchange
and thus the 2010 Affordable Care Act (ACA) highlights care coordination measures. As
a part of the ACA’s meaningful use of care coordination, the Office of the National
Coordinator for Health Information Technology (ONC) has promoted state electronic
Health Information Exchanges (HIE’s) which allow healthcare workers and patients alike
to securely access medical information electronically. Specifically, as part of the ONC’s
vision, pharmacies will participate in Health Information Exchange, but pharmacists are
not eligible to receive any reimbursement for offsetting the cost of electronic health
record (EHR) implementation under CMS’s Electronic Health Records Incentive
Program(US Centers for Medicare and Medicaid 2015). The list of eligible professions
under the EHR incentive program is quite lengthy, including dentists, nurse
practitioners, nurse midwifes, doctors of medicine, osteopathy, surgery, podiatry,
optometry and chiropractors. Additionally, under CMS Meaningful Use stipulations, the
above mentioned professionals are required to provide summary care records during all
transitions among facilities, but not to community pharmacies or community
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pharmacists. Furthermore, Indiana’s HIE, the Indiana Health Information Exchange, does
not engage community pharmacists.
Pharmacists are even further discouraged to engage in care coordination as they are not
recognized providers under the Social Security Act and therefore ineligible to bill
Medicare Transitional Care Management Services’ CPT codes directly (Snow, Beck et al.
2009). Therefore, medication reconciliation during care coordination is billable by most
healthcare providers except pharmacists, who are the medication experts. Despite being
cited as the most trusted and accessible healthcare professional, and despite the fact
that community pharmacies filled over 3.7 billion prescriptions in 2011, community
pharmacists remain underutilized to contribute positively to care coordination.
Regardless of the barriers faced by pharmacists to provide patient care, opportunities
exist for community pharmacists to identify and address health-related problems in the
form of CMRs. Health- related problems can be medication-related in nature, but not
necessarily so. Pharmacists also ameliorate health-related problems related to
preventive-health, as community pharmacists regularly identify and correct missing
preventive-care recommendations by delivering immunizations.
Indeed, one of preventive healthcare’s recent and greatest success has been increased
access to immunizations through community pharmacist-delivered vaccinations.
American community pharmacists began vaccinating in the early 1990’s, and mass
immunization education for pharmacists was endorsed by the US Centers for Disease
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Control and Prevention (CDC) in 1996 (Terrie 2010). Today all 50 state legislations
recognize community pharmacists’ ability to vaccinate, and literature from national data
shows that by allowing pharmacists to provide vaccinations, the rate of influenza
immunization has increased (Steyer, Ragucci et al. 2004). Any time a pharmacist
interacts with a patient is an opportunity to screen for missing vaccinations, especially
during the one-on-one CMR. As such, community pharmacists may intervene on other
preventive care measures, as prevention is reliant on availability and access to
healthcare. Sufficient availability and access however is in stark contrast to the current
state of American healthcare- with its challenges of quality, cost and access, amplified by
a national shortage of primary care providers. Indeed, the Commissioned Corps of
the US Public Health Service has identified pharmacists’ contribution to increasing
preventive care access by serving as extensions of public health infrastructure,
increasing services’ quality, and partnering with other healthcare providers (Scott
Giberson 2011). Because of this, it is reasonable to believe that pharmacies might serve
as care delivery or referral sites for other preventive measures above-and-beyond
vaccinations.
In summary, despite pharmacists’ ability to detect MRPs and omissions in preventive
care, community pharmacists are underutilized in their ability to contribute to care
coordination teams. Furthermore, American laws discourage community pharmacists
from engaging in care coordination. Due to the paucity of literature related to- and
policy hindrance of- community pharmacists’ engagement in care coordination, a study
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specifically analyzing community pharmacists’ efficacy in detecting health-related
problems when engaging in care coordination, in the form of health information
exchange, in preparation for a CMR is warranted.

Study Hypothesis
It is postulated that when community pharmacists engage in care coordination and thus
review patients’ medical histories in preparation for a CMR, that immediate outcomes
(i.e. detection of health-related problems) will improve, but this has yet to be tested.
Touchette et al. studied the effect of pharmacists’ review of medical record during a
CMR on adverse drug event rates, but pharmacists in this study were not in community
settings and information provided to the pharmacists were interpretations of the
medical record (consisting of a two-page standardized synopsis) rather than the
unedited and complete records (Touchette, Masica et al. 2012). Another study
undertaken by Warholak-Juarez et al. within the Indian Health Services explored
pharmacists’ use of medical history. These researchers demonstrated that pharmacists
provide better patient care (i.e. identify and resolve more problems) when given more
complete patient medical histories on which to base their decisions. However,
Warholak-Juarez et al.’s patient cases were also edited and standardized (WarholakJuarez, Rupp et al. 2000). Understanding community pharmacists’ interpretation and
utilization of unedited and complete electronic medical records is warranted. While
pharmacy curricula teaches students to identify health related problems through
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evaluation of standardized medical histories, this model does not reflect current
community pharmacy practice as medical histories HIE information exchange is limited.
Additionally, in the rare chance that health information is shared with community
pharmacists, the information is unedited and non-standardized. Consequently, research
is needed to discern community pharmacists’ effectiveness in discovering health-related
problems during CMR delivery when engaging in care coordination activities.

Research Objectives

Specifically, our research team sought to determine if community pharmacists identify
more health-related problems including MRPs, and omissions of preventive-care. We
seek to answer: “Do pharmacists who review medical records in preparation for a
comprehensive medication review (CMR) identify more MRPs than pharmacists who do
not?,” and characterize the types of MRPs identified between pharmacists who review
medical records and those who do not. Additionally, we aimed to answer: “Do
pharmacists who review medical records in preparation for a comprehensive medication
review (CMR) identify more omissions in recommended preventive care than
pharmacists who do not?,” and characterize types of preventive care omissions found
between community pharmacists who review medical records and those who do not.
We also aimed to characterize the types of health records received from primary care
providers and those records used by community pharmacists to discover health-related
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problems. Lastly, we aimed to ascertain community pharmacists’ perceived usefulness
of available health history, be-it attained from unedited medical records or solely from
the patient.
The research described below may provide evidence towards recognizing community
pharmacists as an integral part of the healthcare team, and allow community
pharmacists to engage in patient-centered collaborative care with prescribers and other
healthcare workers. Long-term, we expect this research will (1) build on existing
evidence demonstrating that pharmacists should be recognized as health care providers
under the Social Security Act and as eligible providers for incentives under the CMS
Electronic Health Record Incentive Program and improve quality and optimization of
MTM services.
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METHODS

This study was designed as a prospective randomized controlled trial to take place
within the Medication Safety Research Network of Indiana (Rx-SafeNet). Rx-SafeNet is a
state-wide community pharmacy practice based research network (PBRN), registered as
an affiliate member with the U.S. Agency for Healthcare Research and Quality (AHRQ)
PBRN Resource Network. The Network, comprised of 181 community pharmacies across
Indiana, serves to facilitate collaboration among researchers and clinicians to research
medication safety and advance community pharmacy. The mission of Rx-SafeNet is to
“improve medication safety and advance community pharmacy practice in Indiana
through the conduct and dissemination of collaborative, patient-centered, practicebased research.”

Outcomes Defined
Planning for the study began in in July 2013 by defining the three outcomes measures.
The primary outcome was total number of MRPs identified per patient as defined by the
taxonomy described in Cipolle, Strand & Morley’s Pharmaceutical Care Process: The
Clinician’s Guide (Cipolle RJ 2004.). A secondary outcome was total number of
preventive care omissions identified per patient, as defined by the 2013 United States
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Preventative Services Task Force A & B Recommendations (See Appendix)(United States
Preventative Services Task Force 2013). The third and final outcome was pharmacist
reported perceptions and beliefs towards utilizing patients’ health history, despite how
it was obtained (i.e. verbally for usual care pharmacists, verbally and from medical
records for intervention pharmacists) for each CMR delivered.

Study Design Timeline
In July 2013, following the Network’s policy for study selection, the project idea was
proposed to the Rx-SafeNet Executive Committee, and approved the same month. RxSafeNet site coordinators voted to pursue the study after voting via an email survey in
August, 2013. A preliminary protocol was developed and subsequently reviewed by the
Rx-SafeNet project review team (PRT) in October 2013.
The PRT is a committee of 3 College of Pharmacy faculty who review draft study
protocols submitted to Rx-SafeNet for feedback on protocol improvement. In
September of 2013, the Purdue University Statistical Consulting service issued guidance
on the protocol’s data analysis methods, and the final protocol was approved by the PRT
in January, 2014. Final approval by the Purdue University Institutional Review Board
occurred on February 25th, 2014.
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Intervention Design
It was decided that the intervention would not be tested in a pre-existing service,
because although limited MTM services occur throughout Indiana and in Rx-SafeNet
locations, use of these consultations for comparison would have been challenging due to
a small number of patients receiving MTM and the wide variety in medication-related
problem taxonomies routinely employed. Therefore, study pharmacists were trained to
provide comprehensive medication reviews (CMRs) with and without care coordination,
as applicable, to create an appropriate comparison group.
The intervention consisted of care coordination in preparation for the CMR by means of
a HIPAA release soliciting the last six months of medical records to the patient-identified
primary care provider by fax. The release itself not only requested records originated by
the primary care provider, but all records obtained by the PCP through care
coordination from other entities. This HIPAA release, explicitly requested release of
protected health information for research purposes. This included the last six months
of: (1) the patient’s problems list; (2) laboratory test results; (3) allergies; (4) the
patient’s medication list; (5) immunization, surgical, device and family history and (6)
the previous six months of known encounters, including any specialist, walk-in, care
coordination, hospital or other healthcare provider encounter. The HIPAA waiver
stipulated if the latest diabetic, osteo-, respiratory, lipid, endocrine, hepatic,
hematological, and/or drug concentration(s) lab results fell outside of the previous six
month window, to transmit the most recent results.

12

The six above criteria were chosen to be requested as they reflect information outlined
at the time by CMS’s Stage1: Eligible Professional Menu Objectives Core Measure 8. This
Core Measure stipulated that any eligible provider who transitioned a patient to another
care setting should provide a care summary to that setting. Currently,
community pharmacists and pharmacies are not eligible providers under this CMS
measure and neither transmit nor receive care summary sheets during transitions of
care.
Thus, both groups of pharmacists received health information, but in two different
approaches. Intervention pharmacists received the patient-health history verbally from
the patient and from the PCP-provided medical record, whereas usual care pharmacists
received health information solely from the patient.

Pharmacist Recruitment as Non-Key Personnel
Community pharmacists were eligible to assist with the study as non-key personnel if
they certified that they did not routinely request medical records from patients’
providers. It was believed that pharmacists who regularly requested patients’ medical
records would have a learning effect on reviewing such history. Recruitment of
community pharmacists within Rx-SafeNet began in March, 2014. Twenty-three
pharmacy site coordinators, representing the 168 pharmacy locations within Rx-SafeNet
at the time, were contacted over the course of three months via email or telephone
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from either the Rx-SafeNet Network Manager or Dr. Gernant. It was at the discretion of
the pharmacy site coordinator to share the study’s information to allow participation
with the then existing recruitment pool of 312 network pharmacists. An estimated 125
pharmacists were informed of the study, as some site coordinators declined
involvement. A total of 10 pharmacists within Rx-SafeNet representing 9 pharmacies,
expressed interest in participating and agreed to undergo research training. However
due to time constraints, only six completed training and three were lost to attrition (See
Figure 1). Five replacement pharmacists were engaged, four of which were within
RxSafeNet. Due to high attrition and low engagement, pharmacist enlistment was
expanded outside the Network, and one non-member of Rx-SafeNet participated in the
study.
Pharmacists were chosen to be the point of randomization as randomization at the
patient level could have potentially contaminated the intervention by learning effects
experienced by the pharmacists. Originally, the study was designed to stratify
pharmacists based on their experience level, defined as year in practice, involvement in
any post-graduate training, and number of CMRs completed in the previous year.
However, this method of stratification was not used due to the high level of attrition;
rather a simple binomial random number generator was used to randomize pharmacists
to either the intervention or usual care group.
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Estimated 125
Pharmacists
Informed of Study

10 Pharmacists
Agreed to Training

4 Dropped Out of
Training

6 Completed
Trained

3 RPhs
Randomized to
Control

2 RPhs
Recruited to
Make up for
Attrition,
Randomized
to Control

Total of 3 RPhs in
the Control group

3 RPhs
Randomized to
Intervention

2 RPh Dropped
Out Due to Time

3 RPhs
Recruited to
Make up for
Attrition,
Randomized
to
Intervention

Figure 1. Study Pharmacist Recruitment and Attrition

1 RPh's
Pharmacy
Closed
1 RPh
Dropped out
Due to Time

Total of 4 RPhs in the
Intervention Group
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Pharmacist Training
One-on-one pharmacist training sessions began after IRB approval in April, 2014. The
seventh and final pharmacist recruited for the study was trained in August, 2014.
Pharmacists were required to complete Human Subjects Research training online
through University of Miami’s Collaborative Institutional Training Initiative (CITI)
modules and undergo one time face-to-face training with Dr. Gernant. Details of these
training sessions are discussed below.

CITI Module Training
All study pharmacists were required to complete Human Subjects Research Training for
Non-Key Personnel through the Collaborative Institutional Training Initiative.
Pharmacists were categorized as non-key personnel as they recruited and consented
patients, but did not contribute in a substantive, measurable way to the study’s
scientific development. Pharmacists were required to complete an integrity assurance
statement certifying that they agreed to the ethical conditions required by CITI training;
namely, pharmacists certified that they would complete CITI training without assistance,
with one active account and without engagement in activities that would improve results
for themselves or others. Required training for non-key personnel included the
following nine modules: (1) A review of the Belmont Report and CITI course
introduction, (2) Students in Research, (3) History and Ethical Principles of Human
Subject Research, (4) Defining Research with Human Subjects, (5) Informed Consent, (6)
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Privacy and Confidentiality, (7) Records-Based Research, (8) Populations in Research
Requiring Additional Considerations and/or Protections, and (9) Conflicts of Interests in
Research Involving Human Subjects. Completion of all eight modules were required,
with an average score of at least 80% on post-module quizzes. Upon completion, a
certificate was generated with the date completed and total score; Dr. Gernant
collected these certificates before study pharmacists were allowed to begin patient
recruitment.

Study-Specific Training
At the commencement of training, pharmacists signed an understanding certifying that
they met all study criteria needed to act as non-key personnel (see Pharmacist
Recruitment as Non-Key Personnel). Pharmacists underwent one-on-one study training
with Dr. Gernant and were given a training manual that included a protocol regarding
CMR delivery. The following sections explain the process of training study pharmacists
on delivering CMRs, the study protocol, how to obtain informed consent and entering
data.

Pharmacist Training: Protocol Training
Protocol training for study pharmacists included a step-by-step introduction to
completing CITI module training, defining patient eligibility, classifying results and data
entry. Additionally, the protocol for intervention pharmacists included instructions on
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how to obtain HIPAA releases and medical records. Intervention pharmacists were
instructed to fax the signed HIPAA release form to the patient-identified primary care
provider at least 10 days before their scheduled CMR. If the pharmacists did not receive
patient records within 48 hours of faxing the HIPAA release, the pharmacist was
instructed to call the prescriber’s office. If the pharmacist received nothing from the
patient’s prescriber’s office within 72 hours before the scheduled CMR, the pharmacist
was instructed to call the prescriber’s office a second time. Intervention patients whose
prescriber’s office did not send records to the pharmacy were excluded from
participation. All pharmacists were at liberty to schedule/reschedule appointments
based on the convenience for the pharmacist and the patient. Pharmacists were
instructed to call the patient 24 hours before their appointment as a reminder.

Pharmacist Training: Informed Consent
Informed consent training was critical as pharmacists participating in the study had no
previous experience consenting patients. In addition to the informed consent training
provided in CITI module training, Dr. Gernant role-played consent with each trainee.
Furthermore, pharmacists were given a list of informed consent policies adapted by the
guidance given by the Purdue University IRB, and reviewed this with Dr. Gernant.
Examples of these policies include delivering informed consent in clear, understandable
every-day language, and allowing the patient to ask questions throughout the process.
The risk of unintended coercion was explained, specifically because the study
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pharmacist may have had a pre-existing relationship with the patient. It was stressed to
study pharmacists that even after reviewing the consent form, many patients may not
yet understand basic information about the risks and benefits of study participation.
Pharmacists were trained to have patients state the study’s purpose and to specifically
explain what was being asked of them in their own words. All pharmacists reported
understanding that patients were ineligible for participation if the patient could not
explain the study in their own words.

Pharmacist Training: Recruitment Logs
Study pharmacists were required to keep recruitment logs, itemizing potential
participants who had been approached and consented for study participation. The
recruitment log served as a record of the number of patients approached for IRB
reporting purposes and CMR scheduling. The log also served as a reminder to
intervention pharmacists to obtain medical records. The recruitment logs were gathered
by Dr. Gernant at the end of the data collection period.

Completing a CMR
Regardless of the level of experience, all pharmacists underwent Medication Therapy
Review (MTR) training delineating differences between a Comprehensive Medication
Review (CMR) and a Targeted Medication Review (TMR). Additionally, pharmacists were
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introduced to the concept of “pharmaceutical care”(Hepler and Strand 1990), in which
pharmacists intervene to prevent, identify and resolve medication problems.
Pharmacists were asked to identify and resolve problems by considering the following
four questions as reflected in the Pharmaceutical Care Process: (1) is the medication
indicated?; (2) Is the medication effective?; (3) Is the medication safe?; and (4) Is the
patient able to adhere to the medication regimen?

Completing a CMR: Extracting Information
Dr. Gernant refreshed pharmacists on the basics of extracting health information by
reviewing the SOAP note process, and the difference between subjective and objective
information. “SOAP” is an acronym for “subjective, objective, assessment, and plan,”
and is a method employed by health care providers to document patient encounters.
This training was included to highlight the difference between study data (identified
MRP’s and preventive care omissions) and clinical decisions made at the discretion of
the pharmacist. A blank SOAP template was provided to study pharmacists to facilitate
reminders to review basic health history (e.g.: vitals, labs).

Completing a CMR: MRPs
Dr. Gernant introduced study pharmacists to categorizing and identifying MRPs by
reviewing the taxonomy described in Cipolle, Strand & Morley’s Pharmaceutical Care
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Process: The Clinician’s Guide (Cipolle RJ 2004.)(see Table 1). In an effort not to limit
pharmacists, examples of MRPs that did not clearly fall into a single classification were
included in a case review. For example, a medication may need adjustment based on
serum concentrations which had not been monitored. If an identified problem was not
easily classified, pharmacists were instructed to choose the classification most closely
related. Additionally, pharmacists were instructed to classify a problem only once, even
if it applied to multiple categories.
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Table 1. MRPs Classification
Category

Unnecessary
drug therapy

Needs
additional drug
therapy

Needs different
drug product

Dosage too low

Adverse drug
reaction

Dosage too
high

Nonadherence

Medication-Related Problem
No valid medical indication for the drug therapy at this time
Multiple drug therapies are being used for a condition that requires
single drug therapy
Medical condition is more appropriately treated with nondrug
therapy
Drug therapy is being taken to treat an avoidable adverse reaction
associated with another medication
Drug abuse, alcohol use, or smoking is causing the medical problem
Medical condition requires the initiation of drug therapy
Preventative drug therapy is required to reduce the risk of
developing a new condition
Medical condition requires additional drug therapy to attain
synergistic or additive effects
Drug product is not the most effective product for the indication
being treated
Medical condition is refractory to the drug product
Dosage form of the drug product is inappropriate
Drug is not effective for the medical problem
Dose is too low to produce the desired response
Dosage interval is too infrequent to produce the desired response
Drug interaction reduces the amount of active drug available
Duration of drug therapy is too short to produce the desired
response
Drug product causes an undesirable reaction that is not dose-related
Safer drug product is required due to risk factors
Drug interaction causes an undesirable reaction that is not doserelated
Dosage regimen was administered or changed too rapidly
Drug product causes an allergic reaction
Drug product is contraindicated due to risk factors.
Dose is too high
Dosing frequency is too short
Duration of drug therapy is too long
Drug interaction occurs in a toxic reaction to the drug product
Dose of the drug was administered too rapidly
Patient did not understand instructions
Patient prefers not to take medication
Patient forgets to take medication
Drug product is too expensive for the patient
Patient cannot swallow or self-administer appropriately
Drug product is not available for the patient
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Completing a CMR: Preventative Care Omissions; the 2013 U.S. Preventative Services
Task Force A & B Recommendations
All pharmacists who were involved in the study attained their PharmD, and thus had
received basic training covering preventive care within the standard Doctor of Pharmacy
curricula. Examples of preventive care measures pharmacists usually receive training on
include colonoscopies, breast and prostate cancer screens, smoking cessation and
aspirin use for myocardial infarction prophylaxis. However, despite their training,
community pharmacists do not routinely engage in preventive care services aside from
vaccination delivery. Therefore, a platform was required to justify the preventive care
measures in which pharmacists could focus their care. Upon literature and policy
review, it was decided that the United States Preventative Task Force (USPSTF) A & B
Recommendations were the most complete and up-to-date list of preventive measures
that applied to the study’s target population.
Prior to training, all study pharmacists had never encountered the USPSTF’s
recommendations. During the section of this training, pharmacists were introduced to
the history and reasons for the USPSTF’s recommendations’ development. Each
recommendation related to adults and seniors were reviewed, however
recommendations’ related to pregnancy and children were excluded, as these patients
were not included in this study for IRB purposes. “Women of child bearing age” was
defined as any female 18-46 years old, in congruence with the USPSTF. “Intimate
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Partner Violence” screening described screening for any physical, sexual, or
psychological harm caused by a current/former partner/spouse occurring in either
heterosexual or same-sex couples. As of 2013, this screening recommendation applied
to women of child-bearing age only.

Completing a CMR: Preventative Measures; The CDC’s Advisory Committee on
Immunization Practices
A refresher on the CDC’s Adult Immunization schedule was included in study training
about preventive care (US Centers for Disease Control and Prevention, 2013).
Pharmacists reviewed information regarding the number of doses, intervals between
doses, recommended vaccination schedule by age group, and important disease-related
information.

Pharmacist Training: Data Recording
The data collection form was developed as an online survey with the Qualtrics® platform
and all pharmacists were instructed to transmit data over the pharmacy’s secure
wireless network, or the secure network identified by both the pharmacist and the
Purdue researchers. The Qualtrics® survey collected data related to patient
demographics, study outcome variables, and included a short survey of the pharmacists’
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perceptions about using the health history obtained, either be it verbal from the
patient, from the medical records or both. Pharmacists had the option of completing
the Qualtrics® survey via iPad, or their work desktop computer.
During training to assure pharmacists understood data entry, Dr. Gernant gave
pharmacists a simulated patient case that included a mock patient’s medical history
(including social/family history), recent labs, medication list, vitals and allergies. The
pharmacist was instructed to review the case, and identify any MRPs and possible
preventive care omissions. Once the case was reviewed, the pharmacist completed a
mock data collection form for practice. If there was any discrepancy in the manner in
which the pharmacists completed the mock data form, Dr. Gernant discussed this with
the pharmacist until an agreement was reached on data transmission.
At the end of each Qualtrics® data collection form was a short survey measuring
pharmacists’ beliefs and attitudes towards utilizing health history in their CMR. Both
intervention and usual care pharmacists were instructed to complete this section, as
both groups did have some health history available to them- namely usual care
pharmacists attained health history verbally from the patient, whereas intervention
pharmacists attained health history from the patient, as well as from unedited medical
records. However, only intervention pharmacists were asked to complete questions
regarding their opinions on usability of certain parts of the medical records, as usual
care pharmacists did not have access to these.
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Patient Eligibility and Recruitment
After study power at 80% with an alpha of 0.05was calculated to detect a minimum
difference of two MRP’s between groups, it was decided 90 patients would be sought
for recruitment, 45 within each group. Patients were recruited face-to-face either by the
study pharmacist or by Dr. Gernant when they visited their community pharmacy to drop
off or pick up a prescription. Pharmacists were given a checklist inclusion and
exclusion criteria and were instructed to ask each potential participant every question
before the invitation for study participation.
Patient inclusion criteria was modeled after Medicare Part D MTM criteria, but expanded
to all adults of all ages to increase the pool of patients for study. Thus
patients were included if they agreed to undergo an CMR with the pharmacist and met
the following criteria: (1) At least four chronic prescription medications scheduled for a
chronic medical condition filled at the study pharmacy; (2) At least one of the following
chronic disease states: hypertension, heart failure, diabetes, dyslipidemia, respiratory
disease (such as asthma, chronic obstructive pulmonary disease, or chronic lung
disorders), bone disease-arthritis (such as osteoporosis, osteoarthritis, or rheumatoid
arthritis), or mental health conditions (such as depression, schizophrenia, bipolar
disorder); (3) had an office visit with their Primary Care Provider within the last six
months for any reason and; (4) understood and were able to give consent. Patients were
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excluded if they met any one of the following criteria: (1) were under 18 years of age;
(2) was a prisoner, or incarcerated; (3) was a university student; (4) was pregnant; (5)
was unable to give informed consent or; (6) had received a CMR from a pharmacist
within the previous six months. Patients were excluded from study participation if they
had received a CMR within the previous six months from a pharmacist, as it was thought
a lasting benefit would be experienced by the patient from their previous visit.

Data Collection Related to Pharmacists
Pharmacist demographics were collected at the time of study training and included
number of years of active practiced, the number of CMRs completed within the previous
year, and if the pharmacist had any post-graduate training/certification (Residency,
Fellowship, or Board Certification). This data was collected to account for differences
among pharmacists delivering the intervention as non-key personnel.

Exit Interviews
Upon study completion, pharmacists were invited to participate in an exit interview with
Dr. Gernant. These interviews served as a quality improvement opportunity for study
pharmacists to provide feedback regarding study logistics, and to discuss barriers and
facilitators for CMR delivery. After consent, pharmacists underwent semi-structured
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private exit interviews using an interview guide either telephonically or face-to-face at
the pharmacists’ pharmacy. Interviews were not audio-recorded, notes and quotations
of pharmacists’ responses were typed during the interview. These transcriptions were
then reviewed for common and emerging themes.

Study Compensation
Pharmacists were compensated at a rate of $75 per CMR, regardless of their assignment
to intervention or usual care groups, which is comparable to market reimbursement for
MTM (Mirixa 2013). If pharmacists in the intervention group did not receive any records
from the PCP despite following procedures, the pharmacy was allowed to invoice the
investigative team $10. It was left to the pharmacists’ discretion to continue and
complete the CMR, however the patient’s data were not included as a part of this study.
Patients were compensated for their time with a $25 Visa gift-card. This compensation
was approved by the Purdue University IRB, with the stipulation that a log of patient’s
identities be recorded to track payment receipt. Patient’s compensation was sent via
mail, with a note of appreciation from the researchers.
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ANALYSIS

The research team consulted with Purdue’s statistical consulting service to develop a
data analysis plan. All analyses for this study were performed using IBM Statistical
Package for the Social Sciences (SPSS) Statistics Version 22.

Pharmacist and Patient Demographics Analysis
Mann-Whitney U tests were used to detect differences in demographic variables (years
practicing and number of CMRs delivered) between pharmacists groups, as pharmacists
were acting as non-key personnel, and differences in experience would expectedly
affect study outcomes. Differences among patient groups’ comorbidities and race were
tested with Pearson chi-square tests or fisher’s exact test for cells that had an expected
count of less than five. Age, number of comorbidities, and total number of medications
taken were compared between groups using Mann-Whitney U tests.

Primary Outcome Analysis: MRPs Identification
The primary outcome, total number of MRPs discovered, was analyzed using an
independent sample Mann-Whitney U test, as the number of MRPs were not normally
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distributed. Significance of the intervention was then tested with a multivariate linear
regression model fit to relate study variables to the number of MRPs discovered. To do
this, bivariate statistics were computed for each predictor variable; bivariates on
categorical data were computed using either a Mann-Whitney or a kruskal-wallis test.
Correlation between continuous data and the number of MRPs identified was computed
with spearman’s rho. Variables with a p-value less than 0.2 were included in a
multivariate linear regression model.
The assumptions of linear regression were verified- linearity was checked with a line of
best fit in a plot of residual vs. predicted values. A correlation matrix and variance
inflation factors/tolerance values were identified to assure that multi co-linearity was
not present, and a durbin-watson test was run to ensure that the residuals were
independent. A p-p-plot was used to verify Homoscedasticity.
The study team also sought to identify if there were differences between groups in the
types of MRP’s identified. Therefore, a Mann-Whitney U test was again used to test for
differences in the numbers of each of the four types of MRP’s (i.e., indication, efficacy,
safety and adherence) identified between groups.

Secondary Outcome Analysis: Preventative-Care Omission Identification
The total number of applicable USPSTF recommendations was calculated for each
patient based on the pharmacist-entered data. Determination of each patient’s number
of applicable recommendations was primarily based on the patient’s age, gender and
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reported comorbidities. If based on the available data it was uncertain to researchers if
a USPSTF recommendation applied to a particular patient, then that recommendation
was counted, as it could not be ruled out. This was done because the USPSTF
recommendations’ purpose is to both screen for and identify possible preventive care
omissions. For example, the USPSTF has several preventive care screening
recommendations for persons who are at risk for sexually-transmitted infections. Those
at risk may be sex industry workers, injection drug users, or those who have multiple
partners; this information was not specifically gathered by the Qualtrics® data collection
form, and therefore could not be ruled out. Healthcare workers utilizing the USPSTF
recommendations need assure patients’ eligibility for each recommendation.
Differences in the number of preventive-care omissions identified between groups were
tested for significance using a t-test. A linear regression model was fit to isolate the
effect of the intervention by the same methods outlined in section 3.1.
The number of preventive care omissions identified for each recommendation was
tested with a chi-square or fishers exact tests.

Secondary Outcome Analysis: Pharmacists’ Perceptions of Utilizing Health History
Pharmacists’ perceptions towards medical history’s usefulness was characterized with
descriptive statistics. Perceptions towards records received and utilized were
characterized with descriptive statistics for intervention group only.
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RESULTS

CMR Completion
Despite replacement for attrition, only four of the seven study pharmacists completed
any CMRs. Due to the high attrition, the low recruitment and the overall slow rate of
CMR completion, researchers decided to include all pharmacists who underwent
training, whether they completed a CMR or not, in exit interviews to identify barriers
and facilitators to study workflow and participation. Two usual care study pharmacists
completed 19 CMRs and three intervention pharmacists completed 17 CMRs between
June, 2014 and February 2015. Of the four pharmacists who completed CMRs, one
usual care pharmacist and one intervention pharmacist had post graduate training. All
pharmacists were female and opted to transmit data via their work desktop computer.
There was no statistical differences in number of CMRs provided in the last year, nor
years practicing between groups. Other demographics related to study pharmacists’
experience can be seen below in Table 2.
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Table 2. Study Pharmacists’ Experience
Usual Care (n=3)
Mean
Number of
CMRs
Provided in Last
Year
Number of
Years Practicing

Min

Max

Intervention (n=2)
Std

Mean

Min

Max

Std

p
0.80

6.7

0

20

11.5

2.5

0

5

3.5

5.0

2

7

2.6

5.5

5

6

0.7

1.00

Patient Demographics
Thirty-six patients were recruited and seen for CMRs during the intervention period; 17
were seen by intervention pharmacists and 19 by usual care pharmacists. The majority
of patients were female (86%) and Caucasian (75%). Patients in the intervention group
were more complex than patients in the usual care group, with significantly more
comorbidities and number of medications, and were more likely to be diagnosed with
asthma, dyslipidemia, obesity and osteoporosis (see Table 3 below). Additionally, there
were significant differences in patients’ race between groups; all intervention patients
were Caucasian and usual care patients were either African American or Caucasian.
There were no differences in the average total number of preventive care omissions
applicable to study patients between groups (14.4± 1.89 vs. 14.5±1.97, p=0.88).
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Table 3. Patient Demographics and Morbidities
Demographics
Age┼
Total # of Medications┼
Total #of Comorbidities┼

Female‡
African American‡
Asian‡
White‡
Comorbidities‡

Intervention (n=17)

Usual Care (n=19)

Median (IQR)

Median (IQR)

45 (39-52)
15 (11-16.5)
5 (4.5-7)

43 (33-49)
8 (6-11)
3 (3-4)

0.20
<0.01*
<0.01*

n (%)
15 (88.2)
0 (0)
0 (0)
17 (100)

n (%)
16 (84.2)
7 (36.8)
2 (10.5)
10 (52.6)

0.56
0.01*
0.49
<0.01*

n (%)

n (%)

Asthma
4 (23.5)
Chronic
5 (29.4)
Pain/Fibromyalgia
Congestive Heart Failure
0 (0)
COPD
2 (11.8)
Depression
9 (52.9)
Diabetes
8 (47.1)
Dyslipidemia
14 (82.4)
GERD
6 (35.3)
Hypertension
15 (29.4)
Obesity
4 (23.5)
Osteoporosis
4 (23.5)
RA
3 (17.6)
‡ Pearson chi-square or fisher’s exact test
┼ Mann-Whitney U test

p-value

0 (0)

0.04*

4 (21.1)

0.71

2 (10.5)
2 (10.5)
8 (42.1)
7 (36.8)
9 (47.4)
3 (15.8)
13 (68.4)
0 (0)
0 (0)
1 (5.3)

0.49
1.00
0.52
0.54
0.01*
0.25
0.24
0.04*
0.04*
0.33

Outcome: MRPs Identified
Intervention pharmacists identified significantly more MRPs per patient than usual care
pharmacists (11 [IQR: 7-14.5] vs. 6 [IQR: 4-9] problems per patient, p=0.02). Intervention
pharmacists found more MRPs in every domain (indication, safety, adherence and
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effectiveness) than usual care pharmacists; that is, intervention pharmacists identified
more: (1) Medical conditions requiring the initiation of drug therapy; (2) Medication
dosages too low to produce the desired response; (3) Medication interactions resulting
in undesirable reactions that were not dose-related; (4) Patients who did not
understand medications’ instructions and (5) Preventative therapies required to reduce
the risk comorbidity development.
Variables identified with bivariate analysis to predict the number of MRPs discovered
included total number of medications, total number of comorbidities, asthma, and
depression. All variables entered into the multiple linear regression model to predict
number of MRPs were significant with the exception of depression, and the overall
model was significant (adjusted R2= 0.511; p<0.01). The intervention, while controlling
for all variables included in the predictor model, was, B= 0.351, CI: 0.005-13.96; p=0.05.
Furthermore, the model improved with the addition of intervention variable into the
model (adjusted R2= 0.461 vs 0.511).

35

70
60

Count

50
40
30
52
40
10

15

20

19

27

26

23

20
12

9

6

0

Medication Related Problem Type

Figure 2. Medication Related Problems Identified

Intervention
Usual Care
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Table 4. MRPs Discovered┼
Intervention

Usual Care

#
Discovered

Median
(IQR)

#
Discovered

Median
(IQR)

U

p

23

0 (0-1.5)

15

0 (0-2)

153.5

0.80

52

3 (2-4)

20

0 (0-2)

264.5

<0.01

75

0 (0-3)

35

0 (0-2)

239.5

0.01

26

0 (0-3)

20

0 (0-2)

162.5

0.98

27

2 (0-2.5)

12

0 (0-2)

218.5

0.07

54

2 (0-4)

32

0 (0-2)

193.5

0.32

40

2 (0-5)

9

0 (0-1)

221.0

0.06

19

0 (0-0)

6

0 (0-0)

169.0

0.827

Safety Total

59

2 (0-6)

15

0 (0-2)

204.0

0.18

Adherence
Total

65

4 (2-6)

46

0 (0-4)

218.5

0.07

MRP Category
Unnecessary
Drug Therapy
Needs
Additional Drug
Indication Total

Needs Different
Drug Product
Dosage Too
Low
Effectiveness
Total

Adverse Drug
Reaction Total
Dosage Too
High

┼ tested for with Mann-Whitney
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Outcome: Preventative Care Omissions Identified
Intervention pharmacists identified, on average, 3.4 preventive care omissions per
patient, compared to an average of 2.5 omissions per patients seen by usual care
pharmacists (a median of 3 [IQR 3-4] vs. a median of 3 [IQR:1-3] omissions identified per
patient; p=0.04). There were statistical differences in types of preventive-care omissions
discovered between groups; intervention pharmacists were more likely than usual care
pharmacists to identify a need for depression screening/counseling, healthy diet
counseling, and missing immunizations. In contrast, usual care pharmacists identified
significantly more patients who needed blood pressure screenings than intervention
pharmacists. Other notable preventive care omissions identified by pharmacists, but
not included in the United States Preventative Service Task Force A & B
recommendations, pertained to healthy amounts of physical activity and accessing
other healthcare resources (e.g., social workers, financial counselors, keeping all
scheduled doctor appointments). Neither intervention nor usual care pharmacists ever
identified preventive care omissions related to breast cancer medications, folic acid
supplementation, intimate partner violence, sexually transmitted diseases, nor skin
cancer behavior. See Table 5 below for a full representation of preventive care
omissions identified by pharmacists.
Only two variables were identified with bivariate analysis to predict the number of
preventive care omissions discovered: hypertension and CHF. When entered into the
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multiple linear regression model to predict number of preventive care omissions
discovered, the model itself was significant (adjusted R2= 0.136; p=0.027). Hypertension
was non-significant, but did increase the predicted model’s r-squared, so it was retained
in the final model testing the effect of the intervention. The model improved with the
addition of the intervention variable from R2= 0.136 to R2= 0.238, and the model
remained significant. The intervention variable itself was significant (B=0.367, CI: 0.1231.88, p=0.027).
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Table 5. Preventative Care Omissions Identified ┼
Preventative Care
Recommendation

Usual Care
Usual Care
#
n (%)
Applicable

Intervention
# Applicable

Intervention
n (%)

pvalue

Alcohol Misuse

19

0 (0%)

17

1 (6%)

0.48

Aspirin Use

4

2 (50%)

9

3 (33%)

0.65

Blood Pressure
Breast Cancer
Preventative
Medicine
Breast Cancer

19

9 (47%)

17

2 (12%)

0.03

16

0 (0%)

15

0 (0%)

--

16

1 (6%)

15

2 (13%)

0.59

Cervical Cancer

16

1 (6%)

15

0 (0%)

1.00

Cholesterol

19

6 (32%)

17

3 (18%)

0.45

Colorectal Cancer

2

2 (100%)

5

6 (100%)

0.11

Depression

19

0 (0%)

17

4 (57%)

0.04

Diabetes

19

6 (32%)

17

5 (29%)

1.00

Falls Prevention

0

1 (-)

0

3 (-)

--

Folic Acid

11

0 (0%)

7

0 (0%)

--

Healthy Diet

19

4 (21%)

17

10 (59%)

0.04

11

0 (0%)

7

0 (0%)

--

19

4 (21%)

17

10 (59%)

0.04

19

1 (6%)

17

4 (24%)

0.17

15

2 (13%)

1.00

0

0 (0%)

--

17

1 (6%)

1.00

17

0 (0%)

--

17

1 (6%)

0.09

Intimate Partner
Violence
Missing
Immunization
Obesity

Osteoporosis
16
2 (13%)
Skin Cancer
0
0 (0%)
Behavioral
Tobacco Use
19
1 (5%)
Sexually
Transmitted
19
0 (0%)
Disease
Other Preventative
19
6 (32%)
Measure
┼ tested with chi-square or fishers exact test
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Outcome: Records Received and Perceived Usefulness
Only one intervention pharmacist was denied access to the patient’s medical record
after multiple attempts, resulting in a 97% response rate from prescriber’s offices.
Additionally, 94% of the time, intervention pharmacists had access to at least one
medical record note. Intervention pharmacists were most likely to receive active
medication lists, allergy lists, problem lists, office visit notes and blood pressure
readings. Intervention pharmacists cited drug levels, active medication lists,
discontinued medication lists, problem lists, order notes, glucose/A1C labs, drug
concentration labs, lung function tests and lipid panels as the most useful pieces of
information (i.e., useful in ≥50% of cases received). Additionally, pharmacists received,
but never utilized the following medical records to discover MRPs: liver/kidney function;
medication indication & start/stop dates; complete blood counts; thyroid stimulating
hormone levels; walk in, care coordination & hospitalization notes; and family, surgical,
device & social history. A graphical representation of perceived usefulness can be seen
in Figures 3 and 4.

Pharmacists’ Perceptions to Utilizing Health History
Intervention pharmacists were more likely to strongly agree or agree they were
comfortable using the health history obtained to make patient specific
recommendations than usual care pharmacists (70.6% vs. 36.8%). Also, intervention
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pharmacists reported that patients’ health information was clearer and more
understandable more often than usual care pharmacists (93.7% vs. 21.1%).
Pharmacists who had access to patient medical records were more likely to agree that
they were confident they identified all of the patient’s MRPs (47.1% vs. 15.8%).
However, neither group was more likely than the other to believe they had actually
resolved all the patient’s medication problems (41.2% vs. 42.1%). Lastly, intervention
pharmacists agreed that the patient’s health history helped them complete a better
CMR more often than usual care pharmacists (100% vs. 68.5%).
See Figure 5 for a full representation of study pharmacists’ opinions in utilizing health
history.
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Figure 3. Records Received and Useful to Intervention Pharmacists
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Figure 4. Medical History’s Usefulness in Detecting Health Related Problems
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Having the patient’s medical records helped me
complete a better CMR

Figure 5. Pharmacist’s Opinions of Utilizing Health History
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Percent Response

I was confident I identified all the medication I was confident I identified created a plan to resolve
related problems the patient had
all the medication related problems the patient had

I was comfortable using the health history to make
patient specific recommendations

The patient’s health history was clear and
understandable

Figure 5. Pharmacist’s Opinions of Utilizing Health History Continued
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Exit Interviews
After pharmacists were interviewed, themes related to barriers and facilitators
emerged; there were a number of limitations due to the low recruitment rate and few
CMRs completed. A major limitation identified by all pharmacists was finding time to fit
in study activities (especially recruitment) into normal workflow responsibilities.

“Time was a huge issue. As a retail pharmacist, even with the
overlap, you still have your own responsibilities.”

Pharmacists also reported limitations related to decision support tools, and identified
confidence issues (concurrent with their feelings they had not resolved all identified
issues) in regards to resolving identified problems.
“I looked up things I learned long ago but hadn’t used in practice.
Interaction checks weren’t helpful. I would get a possible
“serotonin syndrome,’ but I need more research on it. I didn’t
know if I had to be worried about it.”

Time constraints were an emergent theme, and some pharmacists opted to perform the
CMR directly after recruiting the patient, however this was only possible for usual care
pharmacists, as intervention pharmacists had to wait for medical records to be released
from the PCP. Pharmacists who opted to schedule patients, either in the intervention or
usual care groups, identified patient reluctance to attending CMR appointments.
“You really have to sell it to the patients- it’s like I have to pull teeth to
try and help you, and if [it] was your doctor asking, I think they’d be
more likely to do it. I think it’s like, if you have an appointment with a
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prescriber, and you don’t come, you don’t get your prescription….it’s
something that they just don’t see that they need."

Additionally, pharmacists felt that patients may not have responded well to scheduling
CMRs as this was an unfamiliar relationship with the pharmacist.
“People around here, MTM is new, and people aren’t interested
in sitting one on one with a pharmacist. It’s just not a common
thing. They’re used to coming in and talking to us whenever they
want.”

“Patients just weren’t interested, but they just kept avoiding us. I
thought I had one, but they would never come in. I don’t know
why they weren’t interested- maybe it was because they had to
schedule instead of doing it on the fly.”

Several other barriers mentioned by pharmacists were related to workflow issues and
having to complete multiple projects simultaneously. Pharmacists who had devoted
time away from the filling process in a private location found completing CMRs easier
than those who participated in the study between checking prescriptions. By study
design, intervention pharmacists had much more time-requirements; some pharmacists
reported having to review full stacks of patient records before the CMR. However, none
of the intervention pharmacists, upon direct questioning, reported that the records
were ever cumbersome to review. Barriers related to time revolved centrally around
stepping away from prescription filling responsibilities to speak with the patient.
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“I would have to stop and restart because I was getting
interrupted. I would forget what they took last.”

“We are trying to schedule at least one pharmacist as the
MTM pharmacist per day. And they are away from dispensing
in a room so it’s easier to contact people.”

There were few mixed themes reported by pharmacists; specifically pharmacists
identified other pharmacy team members as barriers or facilitators based on whether
the colleague would do extra work while the pharmacist was away from prescription
filling responsibilities.
“I had great techs who could multitask while I was away. The

techs would take the phone calls, type and adjust the pickup
time. They were doing this on their own. Sometimes they would
ask patients to come back tomorrow after dropping off.”

“My manager was supportive; they would cover when I was
talking to patients and then went to a private area.”

Lastly, pharmacists felt positively about delivering CMRs. They voiced they were able to
develop better relationships with patients, and appreciated being able to talk to
patients whom they considered needed their services the most.

“I really liked that I wasn’t restricted in who I could provide the
service to. I could pick people that I felt actually needed the
service. The people I chose were frequent fliers, so it was very
helpful to have their feedback.”
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“In the future, I’ll do more med review to build rapport with the
patients. Not in a room, but over the counter. “The more the
patients get to know me, the more questions they ask. The study
patients, they really stop by now. Even when they don’t have any
prescriptions. They come by to show me their grandkids, and just
talk to me personally.”

“I liked having the time to get to know the patients. I wouldn’t
have known them at all. I feel like I’m more visible to the patients
now.”
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DISCUSSION

In this study, we hypothesized that community pharmacists would be more effective in
detecting health-related problems if they had access to some of the patient’s health
history mirrored to information requested in CMS’ Meaningful Use Stage 1, Core
Measure 8: Transitions of Care Summaries. This core measure dictates that certain
health history be transferred to a receiving healthcare entity; however only “eligible
providers” are counted under this core measure, which exclude pharmacists.
Additionally, only eligible providers can receive incentives through CMS’s Electronic
Health Record Incentives Program which supports the adoption, implementation and
improvement of EHR technology for providers who demonstrate meaningful use. We
hypothesized community pharmacists could add benefit to HIE for two reasons: (1)
pharmacies have the most up-to-date medication list and fill history; and (2)
pharmacist-delivered patient care services (MTM), could be optimized when
pharmacists engage in transitions of care (i.e.: reviewing health information generated
by another healthcare entity). We confirmed that intervention pharmacists found
significantly more MRPs than pharmacists who deliver CMRs under usual care.
Additionally, intervention pharmacists found more MRPs in every single domain (i.e.,
safety, efficacy, indication and adherence) than usual care pharmacists, however these
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differences were only statistically significant for MRPs related to indication. A very
recent study conducted by van Lint, Sorge and Sorensen, had similar results(van Lint,
Sorge et al. 2015); in this study pharmacy residents completed MTM’s without patient
records, and then verified medication problems discovered with pre-existing health
history. Over half of the MRP’s discovered in the van Lint study were related to
indication. MRP’s related to indication may have been discovered most often because
pharmacists are highly educated on indication, but very rarely receive indication
information in usual practice. Nearly significant results related to adherence MRP’s may
have been discovered more often by intervention pharmacists, as patients’ instructions
may have been documented in the medical chart, but never transcribed to the
prescription and subsequently cued the pharmacist to identify discrepancies between
what the patient was instructed, and what the patient actually did.
In addition to discovering more MRP’s, intervention pharmacists also identified more
preventive care omissions than usual care pharmacists overall, however both groups
had certain omissions identified more often than their comparator group. Intervention
pharmacists were more likely to identify omissions related to depression, diet, and
immunizations whereas usual care pharmacists were more likely to identify that the
patient was missing preventive care related to blood pressure screenings. We suspect
intervention pharmacists discovered more missing immunizations because community
pharmacists are highly trained in adult immunizations, but rarely have access to the
patient’s immunization records. We suspect usual care pharmacists were more likely to
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identify blood pressure preventive care omissions because hypertension is a condition
regularly addressed in the community pharmacy setting; intervention pharmacists may
have been more concerned with omissions discovered from the PCP-obtained health
history, as this was not part of their usual practice.
Neither intervention pharmacists nor usual care pharmacists identified any preventive
care omissions related to sexually transmitted diseases nor domestic abuse. We
presume community pharmacists may have felt uncomfortable asking about highly
sensitive subjects and/or may have felt inadequately trained to handle a positive
identification. There is ample room for interventions and research for community
pharmacist knowledge and communication related to preventive care. Specifically,
future research and public health initiatives should focus on community pharmacies as a
delivery point for more comprehensive preventive care, due to their easy access and
employment of trained healthcare providers. Additionally, there were a few cases
where pharmacists found more preventative care omissions than were calculated
applicable by researchers (example: falls prevention and colorectal screening). This
could be explained that pharmacists either identified patients’ need beyond the
stipulations of the USPSTF recommendations. For example, a patient may be at
increased risk of falls if they are under 65, but on medications that cause dizziness and
vertigo. Alternatively, it is possible that pharmacists did not understand the USPSTF
recommendations and misapplied them.
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Intervention pharmacists did find some health history more useful than others. Labs
most useful were related to drug safety and monitoring, such as drug serum levels, A1Cs,
lipid panels and lung function tests; this is expected as community pharmacists
would be more likely to encounter ambulatory chronic diseases (as opposed to critical
care situations with labs such as complete blood counts, and blood gases). Health
history components most useful to the pharmacists were the active/discontinued
medication lists as problem lists. We speculate community pharmacists are routinely
trained to link indications with medications, and may seek out information on
medication and problem lists specifically as community pharmacists rarely receive
indications on prescriptions in usual practice. Indeed, pharmacists found more problems
related to indications than any other medication-related problem. In regards to notes,
order notes were helpful more often to intervention pharmacists than any other type of
visit documentation, including office visits and specialist visits. This could be because
community pharmacists are accustomed to taking orders from physicians, as part of
their normal filling responsibilities. Interestingly, pharmacists perceived a lack of
helpfulness of renal labs. This could be due to the fact that patients might have needed
renal function
Pharmacists were more likely to report the health history they reviewed was clear and
helpful if they received it from the PCP rather than from the patient alone. During the
design of our study, we predicted the possibility that intervention pharmacists could feel
uncomfortable utilizing real, unedited medical records, as certified they did not
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routinely request medical records in order to participate. However, we detected the
opposite, as intervention pharmacists were nearly twice more likely than usual care
pharmacists to report they were comfortable using the health history attained to make
patient specific recommendations. Utilization of real, unedited health information could
particularly help community pharmacists especially when the patient is a poor historian,
has no regular caregiver, and/or has communication/cognitive difficulties. This is further
supported by the fact that usual care pharmacists (i.e., pharmacists who practice under
normal conditions and received health history solely from patients) were less likely to
believe they identified all of the patients’ MRPs. Inferentially, community pharmacists
under normal conditions cannot always be confident that they are aware of all of the
patients’ medications, conditions and needs. Van Lint, Sorge and Sorensen identified
similar results, as pharmacists were more likely to report confidence in the validity of
the MRP identified once they had reviewed the patient’s medical records.
Intervention pharmacists were more than twice as likely than usual care pharmacists to
confidently identify all of the patient’s MRP’s, but were no more likely than usual care
pharmacists to confidently resolve the MRP’s. There are several reasons that may
explain this finding- First, we did not ask pharmacists to resolve problems in this study,
but merely to identify them. Alternatively, this finding could be attributed to confidence
or workflow issues related to the nature of community pharmacy. Namely, resolving
problems identified within community pharmacies is limited as there is lack of
standardization and agreement on community pharmacists’ role, not only by other
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healthcare providers, but within the profession itself. Future research should focus on
why community pharmacists may identify certain healthcare related problems, but not
necessarily act to resolve them.
This study had several limitations; mainly due to the small sample size, few if any
remarks can be made to the clinical relevance to community pharmacy practice. The
suggestions related to the results themselves may be promising, as some significant
suggestions were found, however there may be a low external validity to this study, as
pharmacists were allowed to choose patients themselves. This is not normal practice, as
usually patients are referred to community pharmacists via their Medicare Part D, or
other insurance provider.
Interest in participation of Rx-SafeNet pharmacists in this study was low, and only a
handful of pharmacists expressed initial interest in training, with even fewer completing
training. Pharmacists were compensated for their time, in the form of $150 for training
and $75 per CMR, which is comparable to other common MTM payers’ compensation,
however we speculate that pharmacists may not have been incentivized to participate
as the payment went to the pharmacy itself, and not the pharmacist. This payment
method was utilized as Purdue University mandates individuals be paid only with the
use of consulting agreements. We speculate if pharmacists had been compensated
directly, then there may have been more incentive for study participation. Future
research in community pharmacy PBRNs may find more success in study participation
through direct incentives, and reducing total time spent in study participation by
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reliance on technicians and other pharmacy staff for some study functions, such as the
consent process. Regardless of compensation, pharmacists acting as study personnel in
PBRN research may limit participation and feasibility; as such PBRN studies will be more
successful if pharmacists act as the provider and not as study personnel.
Another limitation due to the lackluster enrollment of pharmacists and high attrition,
was that we could not stratify and match pharmacists based on their experience and
natural variation in ability to appraise medical history. To account for this variation in
clinical skills to the best of our ability, we gathered some demographics on the
pharmacists by asking their past post-graduate training experience and former
experience with delivering CMRs. Experience between the two pharmacists groups was
similar in the average number of years practicing (5.0±2.6 vs. 5.5±0.7), but differed in
relation to CMRs reportedly provided in the last year. While both groups included
members whom reported no experience ever delivering CMRs, usual care pharmacists
had more experience than intervention pharmacists, with an average of 6.7 CMRs/year
vs. 2.5 CMR/s year. One suggestion to reduce this variation was to have a researcher
obtain the medical records, and reduce the pertinent patient information to a
standardized form as previous studies have done, with positive results with regards to
outcomes. However, we decided against an edited medical record form, as the purpose
of this study was to have pharmacists directly review the medical information
themselves, as this is an unusual current circumstance, but a plausible possibility as
transitions of care initiatives are undertaken. We also chose to have pharmacists directly

56

review real, unedited medical records as we wanted to measure pharmacists’ opinions
related to the medical record’s usefulness and usability.
Because usual care pharmacists had moderately more experience delivering CMRs, we
would expect the opposite of this study’s findings, however there was such a small
sample size no definitive conclusions can or should be made.
Another limitation of this study is that the outcomes were not clinical in nature. Study
pharmacists only reported the number of identified health related problems, and not
the patient’s outcome of any action taken (if any action was taken). Any steps taken to
resolve identified health related problems were up to the sole discretion of the study
pharmacist and their clinical judgment; additionally interventions made were not
recorded for this study. Due to this, we are unsure if pharmacists’ confidence in
resolution of MRP’s was low because steps to intervene were never taken, or because
the steps taken were perceived inefficient.
Another limitation results as the quality of records received by intervention pharmacists
was not recorded. No clinical verification was made in how far each medical record went
back in the patient’s history, nor the records’ characteristics; we merely recorded each
type of record received. If we had characterized the quality of the records received, we
may have been able to study pharmacists’ clinical rationalization more closely, and
explain findings related to pharmacists’ comfort and confidence. To characterize the
value pharmacists’ place in medical records more transparently and to mirror transitions
of care efforts in in-patient healthcare, the study was originally designed to include only
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patients who had a recent hospitalization for conditions targeted under CMS’s Hospital
Readmission Reduction Program- namely, CHF, COPD, Pneumonia and Hip/Knee
arthroplasty. However, this was dropped from the final protocol as the patient
recruitment pool would have been diminished. Future research should focus more
specifically on pharmacists’ value and rationalization of medical records in clinical
decision making, and identifying best practices so that they may be taught to future
pharmacists.
Lastly, this study was limited due to demographic differences between patient groups.
Most patients seen in both study groups were females, which is not unexpected, as
females utilize healthcare more often than males(Bertakis, Azari et al. 2000). However,
differences emerged in that intervention patients had significantly more conditions and
medications than usual care patients. It is possible intervention pharmacists were more
aware of existent conditions and medications due to seeing them on the patient’s
medical record, and thus had a more complete list of medications and conditions. Usual
care pharmacists would only know the conditions and medications reported to them by
the patient, and since this study did not verify any information the pharmacists
received, there is no way to assure that these differences identified between groups are
valid. Future research should focus on the quality of transitions of care processesnamely that information being transmitted and appraised is accurate and concise. There
is a wealth of opportunity for research, as the profession needs to understand how it
utilizes electronic health information.
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APPENDIX
U.S. Preventative Services Task Force Recommendations Adapted for Study Pharmacist
Training

Topic
Abdominal aortic
aneurysm

Description
One-time screening for abdominal aortic aneurysm by
ultrasonography in men ages 65 to 75 years who have ever
smoked.

Alcohol misuse

Clinicians screen adults age 18 years or older for alcohol misuse
and provide persons engaged in risky or hazardous drinking with
brief behavioral counseling interventions to reduce alcohol
misuse.

Aspirin

Use aspirin for men ages 45 to 79 years when the benefit due to
a reduction in myocardial infarctions outweighs the potential
harm due to an increase in gastrointestinal hemorrhage.

Aspirin

Use aspirin for women ages 55 to 79 years when the benefit of
reduction in ischemic strokes outweighs the potential harm of
an increase in gastrointestinal hemorrhage.

Blood pressure

Screen for high blood pressure in adults age 18 years and older.

BRCA screening,
counseling about

Women whose family history is associated with an increased
risk for deleterious mutations inBRCA1 or BRCA2 genes be
referred for genetic counseling and evaluation for BRCA testing.

Breast cancer
preventive
medications

Clinicians engage in shared, informed decision making with
women who are at increased risk for breast cancer about
medications to reduce their risk. For women who are at
increased risk for breast cancer and at low risk for adverse
medication effects, clinicians should offer to prescribe riskreducing medications, such as tamoxifen or raloxifene.

Breast cancer
screening

Screen mammography for women, with or without clinical
breast examination, every 1 to 2 years for women age 40 years
and older.
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Cervical cancer
screening

Screen for
cervical cancer in women ages 21 to 65 years with cytology
(Pap smear) every 3 years or, for women ages 30 to 65 years
who want to lengthen the screening interval, screening with a
combination of cytology and human papillomavirus (HPV)
testing every 5 years.

Chlamydial infection Screen for chlamydial infection in all sexually active
screening:
nonpregnant young women age 24 years and younger and for
nonpregnant women older nonpregnant women who are at increased risk.
Cholesterol
abnormalities

Screen men age 35 years and older for lipid disorders.

Cholesterol
abnormalities

Screen men ages 20 to 35 years for lipid disorders if they are at
increased risk for coronary heart disease.

Cholesterol
abnormalities

Screen women age 45 years and older for lipid disorders if they
are at increased risk for coronary heart disease.

Cholesterol
abnormalities

Screen women ages 20 to 45 years for lipid disorders if they are
at increased risk for coronary heart disease.

Colorectal cancer

Depression

Diabetes

Falls prevention

Screen for colorectal cancer using fecal occult blood testing,
sigmoidoscopy, or colonoscopy in adults beginning at age 50
years and continuing until age 75 years.
Screen adults for depression when staff-assisted depression
care supports are in place to assure accurate diagnosis, effective
treatment, and follow-up.
Screen for type 2 diabetes in asymptomatic adults with
sustained blood pressure (either treated or untreated) greater
than 135/80 mm Hg.
Exercise or physical therapy to prevent falls in communitydwelling adults age 65 years and older who are at increased risk
for falls.

Falls prevention in Vitamin D supplementation to prevent falls in communityolder adults: vitamin dwelling adults age 65 years and older who are at increased risk
D
for falls.
Folic acid

All women planning or capable of pregnancy take a daily
supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic
acid.

Gonorrhea screening: Screen all sexually active women, including those who are
pregnant, for gonorrhea infection if they are at increased risk
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for infection (that is, if they are young or have other individual
or population risk factors).
Healthy diet
counseling

Intensive behavioral dietary counseling for adult patients with
hyperlipidemia and other known risk factors for cardiovascular
and diet-related chronic disease. Intensive counseling can be
delivered by primary care clinicians or by referral to other
specialists, such as nutritionists or dietitians.

Hepatitis C virus
infection screening

Screen for hepatitis C virus (HCV) infection in persons at high
risk for infection. The USPSTF also recommends offering onetime screening for HCV infection to adults born between 1945
and 1965.

HIV screening:

Screen for HIV infection in adolescents and adults ages 15 to 65
years. Younger adolescents and older adults who are at
increased risk should also be screened.

Intimate partner
violence screening

Screen women of childbearing age for intimate partner
violence, such as domestic violence, and provide or refer
women who screen positive to intervention services. This
recommendation applies to women who do not have signs or
symptoms of abuse.

Obesity screening and Screen all adults for obesity. Clinicians should offer or refer
counseling
patients with a body mass index of 30 kg/m2 or higher to
intensive, multicomponent behavioral interventions.
Osteoporosis
screening: women

Screen for osteoporosis in women age 65 years and older and in
younger women whose fracture risk is equal to or greater than
that of a 65-year-old white woman who has no additional risk
factors.

Sexually transmitted Recommends high-intensity behavioral counseling to prevent
infections counseling sexually transmitted infections (STIs) in all sexually active
adolescents and for adults at increased risk for STIs.
Skin cancer behavioral The USPSTF recommends counseling children, adolescents, and
counseling
young adults ages 10 to 24 years who have fair skin about
minimizing their exposure to ultraviolet radiation to reduce risk
for skin cancer.
Tobacco use
counseling and
interventions
Syphilis screening

Ask all adults about tobacco use and provide tobacco cessation
interventions for those who use tobacco products.
Screen persons at increased risk for syphilis infection.

